Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

IDH2 mutation + Chr del(1p) + Chr del(19q) + NTRK2 fusion

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

IDH2 mutation + Chr del(1p) + Chr del(19q) (9)

IDH2 mutation + BRAF V600E (2)

IDH2 mutation + Chr del(1p) + Chr del(19q) + BRAF V600E (2)

IDH2 mutation + Chr del(1p) + Chr del(19q) + NTRK1 fusion (2)

IDH2 mutation + Chr del(1p) + Chr del(19q) + NTRK3 fusion (2)

IDH2 mutation + NTRK1 fusion (2)

IDH2 mutation + NTRK2 fusion (2)

IDH2 mutation + NTRK3 fusion (2)

MYC overexpression + IDH2 mutation (2)

IDH1 mutation + Chr del(1p) + Chr del(19q) + NTRK2 fusion (2)

IDH1 mutation + NTRK2 fusion (2)

BAP1 mutation + IDH2 R172W + CDKN2A deletion + CDKN2B deletion (1)

IDH wild-type + FGFR3 S249C + TP53 V73fs (1)

IDH2 mutation + ALK fusion (1)

IDH2 mutation + MGMT promoter methylation (1)

IDH2 mutation + MYC amplification + MAPRE1 overexpression (1)

IDH2 mutation + TMB-L (1)

PIK3CA mutation + IDH2 mutation + Chr del(1q) + Chr del(17) (1)

PIK3CA mutation + TTN mutation + IDH2 mutation + Chr del(1q) + Chr del(17) (1)

BRAF negative + GKAP1-NTRK2 exon 10-16 in-frame fusion (1)

MSI-H/dMMR + NTRK2 fusion (1)

PDGFRA amplification + NTRK2 fusion (1)

STRN-NTRK2 fusion + CDKN2B Deletion (1)

IDH2 mutation + Chr del(1p) + Chr del(19q) + MGMT promoter methylation (0)

IDH2 mutation + Chr del(1p) + Chr del(19q) (9)

IDH2 mutation + BRAF V600E (2)

IDH2 mutation + Chr del(1p) + Chr del(19q) + BRAF V600E (2)

IDH2 mutation + Chr del(1p) + Chr del(19q) + NTRK1 fusion (2)

IDH2 mutation + Chr del(1p) + Chr del(19q) + NTRK3 fusion (2)

IDH2 mutation + NTRK1 fusion (2)

IDH2 mutation + NTRK2 fusion (2)

IDH2 mutation + NTRK3 fusion (2)

MYC overexpression + IDH2 mutation (2)

IDH1 mutation + Chr del(1p) + Chr del(19q) + NTRK2 fusion (2)

IDH1 mutation + NTRK2 fusion (2)

BAP1 mutation + IDH2 R172W + CDKN2A deletion + CDKN2B deletion (1)

IDH wild-type + FGFR3 S249C + TP53 V73fs (1)

IDH2 mutation + ALK fusion (1)

IDH2 mutation + MGMT promoter methylation (1)

IDH2 mutation + MYC amplification + MAPRE1 overexpression (1)

IDH2 mutation + TMB-L (1)

PIK3CA mutation + IDH2 mutation + Chr del(1q) + Chr del(17) (1)

PIK3CA mutation + TTN mutation + IDH2 mutation + Chr del(1q) + Chr del(17) (1)

BRAF negative + GKAP1-NTRK2 exon 10-16 in-frame fusion (1)

MSI-H/dMMR + NTRK2 fusion (1)

PDGFRA amplification + NTRK2 fusion (1)

STRN-NTRK2 fusion + CDKN2B Deletion (1)

IDH2 mutation + Chr del(1p) + Chr del(19q) + MGMT promoter methylation (0)

›

IDH2 mutation + Chr del(1p) + Chr del(19q) + NTRK2 fusion	Oligodendroglioma	IDH2 mutation + Chr del(1p) + Chr del(19q) + NTRK2 fusion	Oligodendroglioma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
IDH2 mutation + Chr del(1p) + Chr del(19q) + NTRK2 fusion	Oligodendroglioma	IDH2 mutation + Chr del(1p) + Chr del(19q) + NTRK2 fusion	Oligodendroglioma	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2